U.S. Biosimilars: The "Devil's In The Details," Sandoz Chief Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Regulatory pathways like 505(b)(2) and BLA, not the new one created through health care legislation, may be best for biosimilars, Sandoz CEO George says.
You may also be interested in...
Biosimilars: Nearly The End Already, Or Is The Best Yet To Come?
Sales of Europe's first round of biosimilars have been poor, prompting some to suggest they're dead before they really got started. Others claim biosimilars' true value will come with the next wave: biosimilar antibodies.
Biosimilars: Nearly The End Already, Or Is The Best Yet To Come?
Sales of Europe's first round of biosimilars have been poor, prompting some to suggest they're dead before they really got started. Others claim biosimilars' true value will come with the next wave: biosimilar antibodies.
Teva Extends Diversification To Lobbying, Not Just Product Mix; Seeks To Join BIO
Teva's application to join the Biotechnology Industry Organization may say as much about BIO as it does about the firm.